$1.18
0.021.72%
Last update: Jul 17, 9:05 AM
15 minutes delayed
Comments
Loading...
Chemomab Therapeutics
CMMBNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Chemomab Therapeutics (NASDAQ:CMMB) Stock, Analyst Ratings, Price Targets, Forecasts
Chemomab Therapeutics Ltd has a consensus price target of $11.75 based on the ratings of 4 analysts. The high is $30 issued by Aegis Capital on December 7, 2021. The low is $4 issued by Maxim Group on May 13, 2024. The 3 most-recent analyst ratings were released by Maxim Group, Oppenheimer, and Roth MKM on May 13, 2024, May 6, 2024, and December 19, 2023, respectively. With an average price target of $5.67 between Maxim Group, Oppenheimer, and Roth MKM, there's an implied 380.23% upside for Chemomab Therapeutics Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
Oppenheimer
Roth MKM
Aegis Capital
1calculated from analyst ratings
Analyst Ratings for Chemomab Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2024 | Buy Now | 238.98% | Maxim Group | Michael Okunewitch | → $4 | Initiates | → Buy | Get Alert |
| 05/06/2024 | Buy Now | 408.47% | Oppenheimer | Jeff Jones | → $6 | Upgrade | Perform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | — | Oppenheimer | Jeff Jones | — | Maintains | Perform | Get Alert |
| 12/19/2023 | Buy Now | 493.22% | Roth MKM | Dylan Dupuis | $7 → $7 | Reinstates | → Buy | Get Alert |
| 10/06/2023 | Buy Now | 493.22% | Roth MKM | Dylan Dupuis | → $7 | Initiates | → Buy | Get Alert |
| 06/07/2023 | Buy Now | — | Oppenheimer | Jeff Jones | — | Downgrade | Outperform → Perform | Get Alert |
| 04/18/2023 | Buy Now | 493.22% | Oppenheimer | Jeff Jones | $12 → $7 | Maintains | Outperform | Get Alert |
| 03/10/2022 | Buy Now | 1594.92% | Oppenheimer | Jeff Jones | $30 → $20 | Maintains | Outperform | Get Alert |
| 12/07/2021 | Buy Now | 2442.37% | Aegis Capital | Nathan Weinstein | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Chemomab Therapeutics (CMMB) stock?
The latest price target for Chemomab Therapeutics (NASDAQ:CMMB) was reported by Maxim Group on May 13, 2024. The analyst firm set a price target for $4.00 expecting CMMB to rise to within 12 months (a possible 238.98% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemomab Therapeutics (CMMB)?
The latest analyst rating for Chemomab Therapeutics (NASDAQ:CMMB) was provided by Maxim Group, and Chemomab Therapeutics initiated their buy rating.
When was the last upgrade for Chemomab Therapeutics (CMMB)?
The last upgrade for Chemomab Therapeutics Ltd happened on May 6, 2024 when Oppenheimer raised their price target to $6. Oppenheimer previously had a perform for Chemomab Therapeutics Ltd.
When was the last downgrade for Chemomab Therapeutics (CMMB)?
The last downgrade for Chemomab Therapeutics Ltd happened on June 7, 2023 when Oppenheimer changed their price target from N/A to N/A for Chemomab Therapeutics Ltd.
When is the next analyst rating going to be posted or updated for Chemomab Therapeutics (CMMB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemomab Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemomab Therapeutics was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
Is the Analyst Rating Chemomab Therapeutics (CMMB) correct?
While ratings are subjective and will change, the latest Chemomab Therapeutics (CMMB) rating was a initiated with a price target of $0.00 to $4.00. The current price Chemomab Therapeutics (CMMB) is trading at is $1.18, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.